An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases.
Evans
Christopher P
CP
Department of Urology, University of California, Davis School of Medicine, 4860 Y St, Suite 3500, Sacramento, CA 95817, USA. christopher.evans@ucdavis.edu
Fleshner
Neil
N
Fitzpatrick
John M
JM
Zlotta
Alexander R
AR
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000379:methods; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors; D019317:Evidence-Based Medicine; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D007987:Gonadotropin-Releasing Hormone; D042944:Cholestenone 5 alpha-Reductase